Callan Family Office’s Regeneron Pharmaceuticals REGN Stock Holding History

Callan Family Office’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.32M	Buy	10,138 +1,102	+12%	+$750K	0.12%	162
2026 Q1	$6.98M	Sell	9,036 -56	-0.6%	-$42.9K	0.16%	138
2025 Q4	$7.02M	Buy	9,092 +2,348	+35%	+$1.59M	0.15%	133
2025 Q3	$3.79M	Buy	6,744 +704	+12%	+$398K	0.12%	177
2025 Q2	$3.17M	Buy	6,040 +4,135	+217%	+$2.31M	0.1%	213
2025 Q1	$1.21M	Buy	1,905 +336	+21%	+$231K	0.09%	190
2024 Q4	$1.12M	Buy	+1,569	New	+$1.32M	0.07%	229
2023 Q2	–	Sell	-786	Closed	-$646K	–	145
2023 Q1	$646K	Buy	+786	New	+$593K	0.16%	82

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Callan Family Office's REGN Position: Q2 2026 in Review

Callan Family Office increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, buying an estimated $750K and bringing the position to 10,138 shares worth $6.32M. The position accounts for 0.12% of the portfolio, ranked #162.

Callan Family Office first reported a position in REGN in Q1 2023 and has held it in 8 quarters since. The position peaked at $7.02M in Q4 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Callan Family Office held 10,138 shares of Regeneron Pharmaceuticals worth $6.32M as of Q2 2026.
Callan Family Office bought 1,102 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $750K.
Regeneron Pharmaceuticals made up 0.12% of Callan Family Office's portfolio in Q2 2026, its #162 holding.
Callan Family Office first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
Callan Family Office's Regeneron Pharmaceuticals position peaked at $7.02M in Q4 2025.
1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.